[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiometabolic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiometabolic-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100561077","phase-1-single-and-multiple-ascending-dose-study-of-amg-513-in-participants-with-obesity-100561077",false,"NCT06585462","Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity","A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity","Inclusion Criteria:\n\n* Participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (BMI) of 30.0 kg\u002Fm\\^2 to 40.0 kg\u002Fm\\^2 for Part A and BMI of 27.0 kg\u002Fm\\^2 to 40.0 kg\u002Fm\\^2 for Part B.\n* Females enrolled must be of non-childbearing potential.\n\nExclusion Criteria:\n\n* History and\u002For clinical evidence of diabetes mellitus, including hemoglobin A1c ≥ 6.5% and\u002For a fasting glucose of ≥ 126 mg\u002FdL (7 mmol\u002FL) at screening.\n* Triglycerides ≥ 5.65 mmol\u002FL (i.e., 500 mg\u002FdL) at screening.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.",[28],"Cardiometabolic Disease",[30,31],"AMG 513","Cardiometabolic disease","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2024-09-09",{"date":40,"type":22},"2026-10-01",{"name":42,"class":43},"Amgen","INDUSTRY",10,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100551950","the-impact-of-faba-bean-rich-bread-on-iron-status-postprandial-lipaemia-and-satiety-100551950","NCT06466746","The Impact of Faba Bean Rich Bread on Iron Status, Postprandial Lipaemia and Satiety","The Impact of Faba Bean Rich Bread on Iron Status, Postprandial Lipaemia and Satiety in Adults with Low Iron Stores","RtP","Inclusion Criteria:\n\n* Non-anaemic, males and pre-menopausal females (must have regular periods)\n* Aged 18-50 years old\n* BMI between 19 - 30 kg\u002Fm2\n* Low iron stores (serum ferritin between 13-40 µg\u002FL for females and 30-90 µg\u002FL for males)\n\nExclusion Criteria:\n\n* Food allergies or intolerances to faba beans (favism) or gluten\n* Diagnosed with anaemia (haemoglobin \\\u003C115 g\u002FL for females or \\\u003C130 g\u002FL for males) or haemochromatosis\n* C-reactive protein (\\>3mg\u002FL)\n* Smokers\n* A history of alcohol abuse (\\> 14 units\u002F week)\n* CVD or medical history of MI or stroke in the past 12 months\n* Diabetes (fasting glucose \\>7.0 mmol\u002FL)\n* Kidney, liver, pancreas or intestinal disease, gastrointestinal disorder or use of drugs likely to alter gastrointestinal function\n* Pregnancy, planning a pregnancy in the next six months or breastfeeding\n* Peri- and post-menopausal women or women with irregular periods\n* Planning on a weight-reducing regimen (lost \\>3kg in last 6 months)\n* Parallel participation in another intervention study\n* Hypertension (blood pressure \\> 140\u002F90 mmHg), cancer, taking medication for hyperlipidaemia (statins), or inflammation\n* Taking vitamin or mineral supplements\n* Donated blood in the last 3 months\n* Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study (such as a pacemaker)","50 Years",{"count":55,"type":22},16,[57],"NA","High levels of animal proteins (meat) in the diet are linked with a greater risk of developing heart disease and other long-term health conditions. Recently there has been a shift to plant-based diets including plant proteins such as pulses, defined as beans, peas, chickpeas and lentils. Pulses are a nutritious and sustainable form of plant protein which are rich in fibre and iron. Despite this, the UK population does not consume the recommended daily amount of pulses (80g\u002Fday equivalent to a large handful). In contrast, bread is commonly consumed but very little is known about how bread enriched with pulses influences the amount of iron that is digested and absorbed by the body as well as risk factors for developing heart disease and type 2 diabetes.\n\nThe main purpose of this randomised controlled cross-over study is to determine how consuming bread enriched with pulses (in the form of faba bean flour at approximately 40% enrichment) compared with conventional white bread (100% wheat flour) influences the amount of iron absorbed in healthy males and females aged 18-50 years with low iron stores. Secondary aims are determining the effects on blood fats and sugar (glucose) and on feelings of fullness (also known as satiety) after eating the bread enriched in pulses and conventional white bread.\n\nParticipants will be required:\n\n* To attend for seven study visits over a period of 60 days.\n* Consume a breakfast meal containing either the faba bean-enriched bread or conventional bread over two study periods, each consisting of one 7 hour study visit and two consecutive visits of 2 hours in duration. After 28 days, participants will return for the second study period as above, with a final study visit conducted 28 days later.\n* Give blood samples during 2 x 7 hour study visits\n* Complete visual analogue scales to rate appetite after consuming the faba bean-enriched and conventional white bread.\n* Record dietary intake prior to and during the study period.",[60,28,61],"Anemia, Iron Deficiency","Low Iron Stores",[63,64,65,66,67,68,69],"faba bean enriched bread","bioavailability","Enrichment of blood haemoglobin with Iron-57 stable isotope","Postprandial Lipaemia","Satiety","Visual analogue scales","Postprandial glycaemia","2024-09-11",{"date":72,"type":36},"2024-09-19",{"date":74,"type":22},"2024-09",{"date":76,"type":22},"2025-09",{"name":78,"class":79},"University of Reading","OTHER",1]